Literature DB >> 24713136

Maximal testosterone suppression in prostate cancer--free vs total testosterone.

Kyle O Rove1, E David Crawford2, Massimo Perachino3, Juan Morote4, Laurence Klotz5, Paul H Lange6, Gerald L Andriole7, Alvin M Matsumoto8, Samir S Taneja9, Mario A Eisenberger10, Leonardo O Reis11.   

Abstract

Testosterone remains a key target in the treatment of advanced prostate cancer. The relationship of free testosterone to prostate cancer treatment and outcomes remains largely unexplored. A consensus of prostate cancer experts was convened in 2013 to review current knowledge surrounding relationship of total and free testosterone to prostate cancer, discuss the free hormone hypothesis, and highlight future avenues for therapeutics. Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24713136      PMCID： PMC4332796          DOI： 10.1016/j.urology.2014.02.001

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  41 in total

1.  Toward excellence in testosterone testing: a consensus statement.

Authors:  William Rosner; Hubert Vesper
Journal:  J Clin Endocrinol Metab       Date:  2010-10       Impact factor: 5.958

2.  Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.

Authors:  Peter S Nelson
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

3.  [Change of the LHRH analogue in progressive castration-refractory prostate cancer].

Authors:  A Heidenreich; D Porres; R Epplen; T van Erps; D Pfister
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 4.  The free hormone hypothesis: a physiologically based mathematical model.

Authors:  C M Mendel
Journal:  Endocr Rev       Date:  1989-08       Impact factor: 19.871

Review 5.  New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.

Authors:  Gerhardt Attard; Juliet Richards; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

6.  Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.

Authors:  Jeremy M Blumberg; Eric O Kwon; T Craig Cheetham; Fang Niu; Charles E Shapiro; Judith Pacificar; Ronald K Loo; Stephen G Williams; Gary W Chien
Journal:  Urology       Date:  2010-12-15       Impact factor: 2.649

7.  Castration-resistant prostate cancer: new science and therapeutic prospects.

Authors:  Joaquim Bellmunt; William K Oh
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

8.  Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.

Authors:  J P Karr; Z Wajsman; R Y Kirdani; G P Murphy; A A Sandberg
Journal:  J Urol       Date:  1980-08       Impact factor: 7.450

9.  Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens.

Authors:  M J Levell; J K Siddall; E Rowe; R W Glashan; M R Robinson; N B Pidcock
Journal:  Prostate       Date:  1987       Impact factor: 4.104

10.  Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin.

Authors:  T J Wilke; D J Utley
Journal:  Clin Chem       Date:  1987-08       Impact factor: 8.327
View more
  8 in total

Review 1.  Estrogen therapy in patients with prostate cancer: a contemporary systematic review.

Authors:  Leonardo Oliveira Reis; Emerson Luis Zani; Herney Andrés García-Perdomo
Journal:  Int Urol Nephrol       Date:  2018-03-29       Impact factor: 2.370

2.  Steroid Hormone Receptors as Potential Mediators of the Clinical Effects of Dutasteride: A Prospective, Randomized, Double-Blind Study.

Authors:  João C C Alonso; Leonardo O Reis; Patrick V Garcia; Ubirajara Ferreira; Wagner E Matheus; Fabiano A Simões; Ronald F Rejowski; Maria Isabel C Alonso-Vale; Wagner J Fávaro
Journal:  Am J Mens Health       Date:  2016-07-08

3.  A novel model to predict positive prostate biopsy based on serum androgen level.

Authors:  Takeshi Ujike; Motohide Uemura; Atsunari Kawashima; Akira Nagahara; Kazutoshi Fujita; Yasushi Miyagawa; Norio Nonomura
Journal:  Endocr Relat Cancer       Date:  2017-10-18       Impact factor: 5.678

Review 4.  How do we define "castration" in men on androgen deprivation therapy?

Authors:  Sarin Itty; Robert H Getzenberg
Journal:  Asian J Androl       Date:  2020 Sep-Oct       Impact factor: 3.285

Review 5.  The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status.

Authors:  Daniel D Bikle
Journal:  JBMR Plus       Date:  2020-11-02

Review 6.  A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications.

Authors:  Anna L Goldman; Shalender Bhasin; Frederick C W Wu; Meenakshi Krishna; Alvin M Matsumoto; Ravi Jasuja
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 25.261

Review 7.  Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?

Authors:  Sonja Cabarkapa; Marlon Perera; Ken Sikaris; Jonathan S O'Brien; Damien M Bolton; Nathan Lawrentschuk
Journal:  Prostate Int       Date:  2017-06-20

8.  Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi).

Authors:  Herjan J T Coelingh Bennink; Jeroen A van Moorselaar; E David Crawford; Erik P M Roos; Diederik M Somford; Ton A Roeleveld; Tjard D de Haan; Harm H E van Melick; Yacov Reisman; Yvette Zimmerman; Gonnie van Osta; Jan Krijgh; Neal D Shore; Fred Saad; Andrew V Schally; Frans M J Debruyne
Journal:  Eur Urol Open Sci       Date:  2021-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.